- Home
- BLRX
BLRX
BioLineRx Ltd.
as 10-28-2025 4:00pm EST
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
| Founded: | 2003 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 17.1M | IPO Year: | 2011 |
| Target Price: | $19.00 | AVG Volume (30 days): | 28.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.30 - $22.60 | Next Earning Date: | 11-24-2025 |
| Revenue: | $17,251,000 | Revenue Growth: | 1.19% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BioLineRx Ltd. News
BLRX Breaking Stock News: Dive into BLRX Ticker-Specific Updates for Smart Investing
TipRanks
5 months ago
BioLineRx upgraded to Buy from Hold at JonesResearch
Benzinga
5 months ago
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
MT Newswires
5 months ago
Sector Update: Health Care
MT Newswires
5 months ago
Top Premarket Gainers
PR Newswire
5 months ago
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
Zacks Small Cap Research
5 months ago
BLRX: First Quarter Results
GuruFocus.com
5 months ago
BioLine Rx Ltd (BLRX) Q1 2025 Earnings Call Highlights: Transformational Moves and Financial ...
PR Newswire
5 months ago
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
Compare BLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BLRX BioLineRx Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.